osimertinib,
Tagrisso,
Osimertinib mesylate [USAN],
RDL94R2A16,
Osimertinib mesylate (USAN),
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide methanesulfonate,
osimertinib mesilate,
osimertinib-mesylate,
Tagrisso (TN),
osimertinib monomesylate,
AZD 9291 mesylate,
osimertinib methanesulfonate,
AZD-9291 mesylate,
Osimertinib mesilate (JAN),
CHEMBL3545063,
SCHEMBL14661152,
CHEBI:90948,
BCP09934,
EX-A1577,
KS-00000SU8,
HY-15772A,
MFCD28137994,
AKOS026673944,
1421373-66-1,
DS-9913,
SB22953,
2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, methanesulfonate (1:1),
AC-29022,
AK198680,
BC600811,
FT-0699962,
D10766,
AZD-9291 mesylate pound Osimertinib Mereletinib),
AZD9291 Ms salt, Osimertinib Ms salt; Mereletinib Ms salt,
AZD9291 mesylate,
N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide methanesulfonate,
N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide;methanesulfonic acid,
osimertinib,
AZD9291 methanesulfonate,
ACN-036296,
CS-2019,
C000603933,
Osimertinib mesylate,
AZD-9291 (Mesylate),
Mereletinib mesylate,
Tagrisso,
UNII-RDL94R2A16,